An active revascularization strategy, i.e. recanalization of a CTO, might improve function in non-infarcted hibernating myocardium and promote infarct healing at the border zones. These effects may attenuate the remodeling process, which may lead to…
ID
Bron
Verkorte titel
Aandoening
1. ST-elevation myocardial infarction (STEMI);
2. percutaneous coronary intervention;
3. Chronic total occlusion;
4. left ventricular function;
NLD:
ST-elevatie myocard infarct (STEMI),
percutane coronaire interventie,
chronische totale occlusie,
linker ventrikel functie.
Ondersteuning
Academic Medical Center ¨C University of Amsterdam
Department of cardiology
The Netherlands
Principal investigators:
R.J. van der Schaaf, MD
R.J. de Winter, MD, PhD
J.P. Henriques, MD, PhD
Abbott Vascular
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Measured by cardiac MRI at four months:<br>
1. Left ventricular ejection fraction;<br>
2. Left ventricular end-diastolic volume.
Achtergrond van het onderzoek
Multi-center, randomized, prospective two-arm trial in approximately 300 Patients with acute myocardial infarction treated with primary PCI and with a non-infarct related CTO. Patients are randomized to either PCI of the CTO or no CTO intervention after STEMI. Blinded evaluation of endpoints to determine whether PCI of the CTO within seven days after STEMI (versus no CTO intervention) results in a higher left ventricular ejection fraction and a lower left ventricular end-diastolic volume assessed by MRI at four months.
Doel van het onderzoek
An active revascularization strategy, i.e. recanalization of a CTO, might improve function in non-infarcted hibernating myocardium and promote infarct healing at the border zones. These effects may attenuate the remodeling process, which may lead to improved global LV function, decreased LVEDV, and improved survival.
Onderzoeksopzet
1. Initial selection and informed consent;
2. Randomization: PCI of the CTO/No CTO intervention;
3. Hospital discharge;
4. 30 day follow-up;
5. 4 month follow-up;
6. 12 month follow-up;
7. 2 year follow-up;
8. 3 year follow-up;
9. 4 year follow-up;
10. 5 year follow-up.
Onderzoeksproduct en/of interventie
PCI of the non-infarct related CTO within seven days after primary PCI for STEMI versus no CTO intervention within one year after inclusion.
Publiek
P.O. box 22660
René J. Schaaf,van der
Amsterdam 1105 AZ
The Netherlands
+31 20 5664585
+31 20 5664585
Wetenschappelijk
P.O. box 22660
René J. Schaaf,van der
Amsterdam 1105 AZ
The Netherlands
+31 20 5664585
+31 20 5664585
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients after successful primary PCI for STEMI are screened for entry into this trial. A primary PCI is ¡®successful¡¯ when the residual stenosis of the culprit lesion < 50% and the TIMI flow ¡Ý 2.
Patients are suitable for inclusion in this trial if coronary angiography preceding the primary PCI reveals at least one chronic total occlusion with all of the following characteristics:
1. Located in a non-infarct related coronary artery:
a. In the left coronary system if the right coronary artery (RCA) is the culprit lesion;
b. In the RCA or left circumflex artery (LCX) if the left anterior descending artery (LAD) is culprit lesion;
c. In the RCA or LAD if the LCX is the culprit lesion;
2. A 100% luminal narrowing without antegrade flow or with antegrade or retrograde filling through collateral vessels;
3. Amenable to PCI treatment;
4. A reference diameter of ¡Ý 2.5 millimeters.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Older than 80 years of age;
2. Persistent or permanent atrial fibrillation;
3. Known renal insufficiency (e.g. serum creatinine level of more than 265 ¦Ìmol/L (i.e. more than 3.5 mg/L));
4. More than 48 hours of hemodynamic instability after primary PCI, defined as pre-shock (heart rate >100/min. and or systolic blood pressure <100 mmHg) or shock (sustained systolic blood pressure ¡Ü 80 mmHg despite fluid hydration with ¡Ý two low dose or one high dose vasopressor or inotropic drug(s) or a cardiac index of ¡Ü 2.2 liters per minute per square meter of body-surface area and a pulmonary-capillary wedge pressure of at least 15 mmHg if known);
5. Cardiac events between primary PCI and randomization:
a. Extended myocardial infarction, as evidenced by a new episode of chest pain with new ST-segment elevations and a new CK / CK-MB peak;
b. Acute stent thrombosis;
c. Ventricular arrhythmias, i.e. sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) more than 48 hours after primary PCI (i.e. late ventricular arrhythmia);
6. Significant left main stenosis (diameter stenosis ¡Ý 50%);
7. Indication for Coronary Artery Bypass Grafting (CABG);
8. Severe valvular heart disease requiring cardiac surgery within four months;
9. Indication for implantable cardioverter defibrillator (ICD) within four months;
10. Inability to schedule the index procedure within seven days after primary PCI;
11. Unsatisfactory baseline investigations, i.e. MRI not suitable for endpoint assessment;
12. Any contraindication for MRI, i.e.:
a. pacemaker;
b. cerebrovascular clips;
c. claustrophobia;
13. Serious known concomitant disease with a life expectancy of less than one year;
14. Circumstances that prevent follow-up (no permanent home or address, transient, etc.);
15. Previous participation in this trial or any other trial within the previous 30 days.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1075 |
| NTR-old | NTR1108 |
| Ander register | Explore : IA 107001. |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |